These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 22660659)
1. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Morgan RD; O'Callaghan JM; Knight SR; Morris PJ Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659 [TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178 [TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428 [TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials. Zheng J; Song W Medicine (Baltimore); 2017 Jul; 96(28):e7151. PubMed ID: 28700465 [TBL] [Abstract][Full Text] [Related]
5. Induction therapy in renal transplant recipients: how convincing is the current evidence? Wagner SJ; Brennan DC Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670 [TBL] [Abstract][Full Text] [Related]
7. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal. Saull HE; Enderby CY; Gonwa TA; Wadei HM Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849 [TBL] [Abstract][Full Text] [Related]
8. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin. Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622 [TBL] [Abstract][Full Text] [Related]
9. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781 [TBL] [Abstract][Full Text] [Related]
10. Basiliximab: a review of its use as induction therapy in renal transplantation. Chapman TM; Keating GM Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis. Hwang SD; Lee JH; Lee SW; Park KM; Kim JK; Kim MJ; Song JH Transplant Proc; 2018 May; 50(4):987-992. PubMed ID: 29731098 [TBL] [Abstract][Full Text] [Related]
12. Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up. Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW Transpl Immunol; 2017 Feb; 40():42-50. PubMed ID: 27888093 [TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation. Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis. Shou ZF; Zhou Q; Cai JR; Cheng J; He Q; Wu JY; Chen JH Chin Med J (Engl); 2009 Jul; 122(14):1692-8. PubMed ID: 19719973 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis. Hao WJ; Zong HT; Cui YS; Zhang Y Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005 [TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review. Zhang X; Huang H; Han S; Fu S; Wang L Transpl Immunol; 2012 Oct; 27(2-3):63-8. PubMed ID: 22960043 [TBL] [Abstract][Full Text] [Related]
17. Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study. Hellemans R; Hazzan M; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Noël C; Abramowicz D Am J Transplant; 2015 Jul; 15(7):1923-32. PubMed ID: 25707875 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis. Shao M; Tian T; Zhu X; Ming Y; Iwakiri Y; Ye S; Ye Q Oncotarget; 2017 Sep; 8(39):66426-66437. PubMed ID: 29029524 [TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. Lentine KL; Schnitzler MA; Xiao H; Brennan DC Trials; 2015 Aug; 16():365. PubMed ID: 26285695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]